Personal Introduction

Education:

• 2004.9 – 2009.7     Ph.D. in Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Science, China.

• 2000.9 – 2004.6     B.S. in Biological Sciences, Nankai University, Tianjin, China

Professional Positions:

• 2019.1 – present     Principle Investigator, Department of Pathophysiology, , Shanghai China

• 2013.6 – 2018.12     Postdoctoral Fellow/ Assistant Instructor/Instructor, Internal Medicine, UT Southwestern Medical Center at Dallas

• 2009.9 – 2013.5     Postdoctoral Fellow, Molecular and Cell Biology, University of California at Berkeley

• 2004.7– 2009.8     Ph.D., Shanghai Institutes for Biological Sciences, Chinese Academy of Science, Shanghai, CHINA

Research Interests

• Programmed cell death is crucial for multiple physiological processes of multicellular organisms, and its dysregulation is closely related to a variety of human diseases, such as cancers, neurodegenerative diseases and ischemic diseases. Recent evidence shows that programmed cell death is not only limited to apoptosis, but also necrosic cell death are comprehensively regulated. Therefore, the role and molecular mechanisms of programmed cell death in human diseases and its implications in clinical therapy have always been the focus of our research.

• Dr. Zhang utilizes biochemistry, molecular and cell biology, model animals, and compound screening to dissect the molecular mechanisms of oxidative stress induced necrotic cell death, and explore its clinical potentials for ischemic diseases and fibrotic diseases. It mainly contains the following aspects:

• (1) Post-translational modification in ferroptosis and its effect in liver diseases;

• (2) The role of ferroptosis in cellular metabolism, cancer metastasis, and cancer therapy.

Scientific Research Projects

• National Natural Science Foundation of China (32070734), 2021/01/01 to 2024/12/31, 580,000 RMB, ongoing, Jing Zhang (PI), Goal: Ubiquitin ligase Mule in ferroptosis and liver diseases

• Shanghai Pujiang Program (20PJ1409500), 2020/11 to 2022/10/30, 300,000 RMB, ongoing, Jing Zhang (PI), Goal: oxidative stress induced necrosis and kidney injury

• Natural Science Foundation of Shanghai (20ZR1430800), 2020/07 to 2023/06, 200,000 RMB, ongoing, Jing Zhang (PI), Goal: the ubiquitination of transferrin receptor in ferroptosis

Publications

1. Yan Wu; Huike Jiao; Yangbo Yue; Kang He; Yuting Jin; Jiang Zhang; Jing Zhang; Yuehan Wei;Hanyan Luo; Zhenyue Hao; Xuyun Zhao; Qiang Xia; Qing Zhong; Jing Zhang ; Ubiquitin ligase E3 Huwe1/Mule targets transferrin receptor for degradation and suppresses ferroptosis in acute liver injury, Cell Death and Differentiation, 2022, DOI:10.1038/s41418-022-00957-6.

2. Jing Zhang; Qing Zhong; Histone deacetylase inhibitors and cell death., Cellular and Molecular Life Sciences, 2014, 71(20): 3885-3901.

3. Jing Zhang; Shu Kan; Brian Huang; Zhenyue Hao; Tak W. Mak; Qing Zhong; Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2, Genes&Development, 2011, 25(24): 2610-2618.

4. Jing Zhang; Liping Song; Ying Huang; Qian Zhao; Kewen Zhao; Guoqiang Chen; Accumulation of hypoxia-inducible factor-1 alpha protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid, Haematologica, 2008, 93(10): 1480-1487.

5. Liping Song; Jing Zhang; Shaofang Wu; Ying Huang; Qian Zhao; Jingping Cao; Yingli Wu; Lishun Wang; Guoqiang Chen; Hypoxia-inducible factor-1a-induced differentiation of myeloid leukemic cells is its transcriptional activity independent, Oncogene, 2008, 27(4): 519-527.